1. Home
  2. NMFC vs COLL Comparison

NMFC vs COLL Comparison

Compare NMFC & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NMFC
  • COLL
  • Stock Information
  • Founded
  • NMFC 2010
  • COLL 2002
  • Country
  • NMFC United States
  • COLL United States
  • Employees
  • NMFC N/A
  • COLL N/A
  • Industry
  • NMFC Finance/Investors Services
  • COLL Biotechnology: Pharmaceutical Preparations
  • Sector
  • NMFC Finance
  • COLL Health Care
  • Exchange
  • NMFC Nasdaq
  • COLL Nasdaq
  • Market Cap
  • NMFC 1.2B
  • COLL 958.8M
  • IPO Year
  • NMFC 2011
  • COLL 2015
  • Fundamental
  • Price
  • NMFC $10.62
  • COLL $30.51
  • Analyst Decision
  • NMFC Hold
  • COLL Strong Buy
  • Analyst Count
  • NMFC 3
  • COLL 4
  • Target Price
  • NMFC $11.00
  • COLL $43.75
  • AVG Volume (30 Days)
  • NMFC 479.8K
  • COLL 282.0K
  • Earning Date
  • NMFC 07-30-2025
  • COLL 08-07-2025
  • Dividend Yield
  • NMFC 12.34%
  • COLL N/A
  • EPS Growth
  • NMFC N/A
  • COLL N/A
  • EPS
  • NMFC 0.99
  • COLL 1.25
  • Revenue
  • NMFC $366,773,000.00
  • COLL $664,283,000.00
  • Revenue This Year
  • NMFC N/A
  • COLL $20.04
  • Revenue Next Year
  • NMFC N/A
  • COLL $3.98
  • P/E Ratio
  • NMFC $10.73
  • COLL $24.37
  • Revenue Growth
  • NMFC N/A
  • COLL 17.17
  • 52 Week Low
  • NMFC $8.84
  • COLL $23.23
  • 52 Week High
  • NMFC $12.55
  • COLL $42.29
  • Technical
  • Relative Strength Index (RSI)
  • NMFC 54.34
  • COLL 60.67
  • Support Level
  • NMFC $10.44
  • COLL $29.28
  • Resistance Level
  • NMFC $10.70
  • COLL $30.83
  • Average True Range (ATR)
  • NMFC 0.17
  • COLL 0.73
  • MACD
  • NMFC 0.01
  • COLL 0.01
  • Stochastic Oscillator
  • NMFC 71.21
  • COLL 81.71

About NMFC New Mountain Finance Corporation

New Mountain Finance Corp is a closed-end, non-diversified management investment company. It invests in equity interests such as preferred stock, common stock, warrants, or options received in connection with debt investments or may include direct investment in the equity of private companies. The company's investment objective is to generate current income and capital appreciation through sourcing and origination of debt securities at all levels of the capital structure, including first and second-lien debt, notes, bonds and mezzanine securities.

About COLL Collegium Pharmaceutical Inc.

Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.

Share on Social Networks: